Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UBB antisense RNA 1 (UBB-AS1) is presumed to be a non-coding antisense transcript at the UBB locus, possibly involved in regulation of UBB gene expression by RNA-based mechanisms, as with other antisense RNAs. However, there is insufficient published data to specify its sequence, structure, cellular role, clinical relevance, or therapeutic target potential. Most disease- and biologically relevant evidence centers on the UBB gene and the pathogenic mutant UBB+1, which are associated with proteasome dysfunction, neurodegeneration, and cell death, rather than any specific antisense transcript. Key Point: No substantive, experimentally validated information is available for "UBB antisense RNA 1" as a molecular target. The entry may reflect a mistaken, incomplete, or hypothetical entity rather than a true canonical target in biomedical literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UBB antisense RNA 1 (UBB-AS1).